Paratek Pharmaceuticals Announces Inclusion of Oral NUZYRA® in China’s National Reimbursement Drug List
December 13 2023 - 8:53AM
Paratek Pharmaceuticals, Inc., a biopharmaceutical company focused
on the development and commercialization of innovative therapies
for life-threatening diseases and other public health threats,
today announced that China’s National Healthcare Security
Administration (NHSA) has added the oral formulation of NUZYRA®
(omadacycline) to the country’s National Reimbursement Drug List
(NRDL) for treatment of community-acquired bacterial pneumonia
(CABP) and acute bacterial skin and skin structure infections
(ABSSSI). Earlier this year, NHSA added the intravenous (IV)
formulation of NUZYRA to the NRDL for the treatment of CABP and
ABSSSI.
“The addition of oral NUZYRA to China’s NRDL allows millions of
patients increased accessibility, at reduced prices, to the
once-daily oral and IV formulations of this life-saving therapy for
serious community-acquired infections,” said Evan Loh,
M.D., Paratek chief executive officer. “This inclusion further
expands China’s antibiotic armamentarium to address antimicrobial
resistance, an ever-growing, urgent, global public health crisis.
We are grateful to the NHSA for their continued recognition of the
clinical benefit, safety and compelling value proposition that
life-saving medicines such as NUZYRA provide to patients. We
applaud our partner Zai Lab for their continued commitment to
bringing NUZYRA to patients in China.”
NUZYRA was granted approval by the U.S. Food and Drug
Administration in October 2018 and Paratek launched the product in
the United States in February
2019. Paratek’s partner in China, Zai Lab Limited
(NASDAQ: ZLAB; HKEX: 9688), received approval of both
IV and oral NUZYRA as a Category 1 innovative drug by
the National Medical Products Administration (NMPA) of
China for the treatment of CABP and ABSSSI in December
2021.
About Paratek Pharmaceuticals,
Inc. Paratek Pharmaceuticals, Inc. is a
biopharmaceutical company focused on the development and
commercialization of innovative therapies for life-threatening
diseases and other public health threats.
The company’s lead commercial product, NUZYRA (omadacycline), is
a once-daily oral and intravenous antibiotic available in the
United States for the treatment of adults with community-acquired
bacterial pneumonia (CABP) and acute bacterial skin and skin
structure infections (ABSSSI). Paratek has a collaboration
agreement with Zai Lab for the development and commercialization of
omadacycline in the greater China region and retains all remaining
global rights.
Paratek is also conducting a Phase 2b study with NUZYRA in a
rare disease, non-tuberculous mycobacterial (NTM) pulmonary
disease, caused by Mycobacterium abscessus complex. Paratek
estimates this opportunity represents a potential $1 billion
addressable market in the United States.
For more information, visit www.ParatekPharma.com or
follow us on LinkedIn and Twitter.
About NUZYRA NUZYRA (omadacycline) is a
novel antibiotic with both once-daily oral and intravenous (IV)
formulations for the treatment of community-acquired bacterial
pneumonia (CABP) and acute bacterial skin and skin structure
infections (ABSSSI). A modernized tetracycline specifically
designed to overcome tetracycline resistance, NUZYRA exhibits
activity against a multitude of Gram-positive,
Gram-negative, atypicals and other drug-resistant
bacterial strains that cause serious infections.
Media Contact: Christine Fanelle Scient
PR Christine@scientpr.com Phone: 215-595-5211
Zai Lab (NASDAQ:ZLAB)
Historical Stock Chart
From Apr 2024 to May 2024
Zai Lab (NASDAQ:ZLAB)
Historical Stock Chart
From May 2023 to May 2024